comparemela.com

Latest Breaking News On - Patients beyond - Page 7 : comparemela.com

Antengene To Present Latest Results from TORCH-2 Study of ATG-008 in Advanced Solid Tumors in Poster Discussion at ASCO 2023

/PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to.

Beijing
China
Australia
Singapore
South-korea
Chicago
Illinois
United-states
Mccormick-place
Shanghai
Hong-kong
Taiwan

Antengene Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers

Antengene Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states
Australia
Hong-kong
South-korea
Singapore
China
Taiwan
Shanghai
American
Peter-qian
Asia-pacific
Prnewswire-antengene-corporation-limited

Antengene Announces NDA Submission for XPOVIO® in Indonesia

SHANGHAI and HONG KONG, May 17, 2023 /PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted New Drug Applications (NDAs) for XPOVIO® (selinexor) to the Indonesia National Agency of Drug and Food.

Thailand
Malaysia
Taiwan
Shanghai
China
Australia
Singapore
South-korea
Indonesia
Hong-kong
Peter-qian
Jay-mei

Antengene Announces NDA Submission for XPOVIO in Indonesia

SHANGHAI and HONG KONG, May 17, 2023 /PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted New Drug Applications (NDAs) for XPOVIO (selinexor) to the Indonesia National Agency of Drug and Food Control (BPOM) for the treatment of relapsed/refractory multiple myeloma (R/R MM) and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). In Q4 2022, Antengene also submitted NDAs for XPOVIO in Malaysia and Thailand. "In just six months, we have submitted NDAs for XPOVIO in three ASEAN countries, Malaysia, Thailand and Indonesia, supporting our plans to expand commercial presence in the APAC region," said Thomas Karalis, Antengene's Corporate Vice President, Head of Asia Pacific Region. "In a region

South-korea
Taiwan
Singapore
Hong-kong
Thailand
Shanghai
China
Indonesia
Australia
Malaysia
Asia-pacific
Peter-qian

Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031

Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Bo-shan
Shandong
China
South-korea
Hong-kong
Taiwan
Australia
Singapore
United-states
American
Asia-pacific
Jay-mei
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.